Chapter 21

Bevacizumab for Recurrent Glioma - A Personal View

Roger Stupp

Abstract

<p>Treatment of recurrent glioma remains a therapeutic challenge. Unprecedented high response rates associated with rapid clinical improvement have been observed. Despite the absence of definitive data and while definitive trial has not even been started, regulatory approval was requested. And while the United States Food and Drug Administration granted accelerated approval based on 2 small uncontrolled phase II trials, the European Medicines Agency rejected the application.</p>

Total Pages: 133-139 (7)

Purchase Chapter  Book Details

RELATED BOOKS

.Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers.
.Frontiers in Anti-Cancer Drug Discovery.
.Current and Future Application of Artificial Intelligence in Clinical Medicine.
.Thrombosis in Cancer: .